Wells Fargo’s Agile Therapeutics AGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-19
| Closed | -$37 | – | 7839 |
|
|
2023
Q4 | $37 | Buy |
19
+5
| +36% | +$10 | ﹤0.01% | 7014 |
|
|
2023
Q3 | $34 | Buy |
14
+7
| +100% | +$17 | ﹤0.01% | 7032 |
|
|
2023
Q2 | $21 | Buy |
7
+1
| +17% | +$5 | ﹤0.01% | 7297 |
|
|
2023
Q1 | $72 | Hold |
6
| – | – | ﹤0.01% | 7019 |
|
|
2022
Q4 | $63 | Buy |
6
+1
| +20% | +$12 | ﹤0.01% | 6937 |
|
|
2022
Q3 | $0 | Buy |
5
+2
| +67% | +$49 | ﹤0.01% | 7765 |
|
|
2022
Q2 | $0 | Buy |
3
+2
| +200% | +$290 | ﹤0.01% | 7864 |
|
|
2022
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 8180 |
|
|
2021
Q4 | $1K | Hold |
1
| – | – | ﹤0.01% | 7126 |
|
|
2021
Q3 | $2K | Hold |
1
| – | – | ﹤0.01% | 6623 |
|
|
2021
Q2 | $4K | Sell |
1
-10
| -91% | -$33K | ﹤0.01% | 6426 |
|
|
2021
Q1 | $47K | Sell |
11
-70
| -86% | -$378K | ﹤0.01% | 5842 |
|
|
2020
Q4 | $468K | Buy |
81
+56
| +224% | +$330K | ﹤0.01% | 4568 |
|
|
2020
Q3 | $154K | Buy |
25
+7
| +39% | +$40.1K | ﹤0.01% | 5092 |
|
|
2020
Q2 | $100K | Buy |
18
+17
| +1,700% | +$88.3K | ﹤0.01% | 5224 |
|
|
2020
Q1 | $3K | Sell |
1
-3
| -75% | -$17.2K | ﹤0.01% | 5962 |
|
|
2019
Q4 | $20K | Buy |
+4
| New | +$14K | ﹤0.01% | 5747 |
|
|
2019
Q1 | – | Sell |
-1
| Closed | -$1K | – | 6582 |
|
|
2018
Q4 | $1K | Sell |
1
-12
| -92% | -$18.4K | ﹤0.01% | 6329 |
|
|
2018
Q3 | $10K | Hold |
13
| – | – | ﹤0.01% | 6000 |
|
|
2018
Q2 | $13K | Buy |
13
+12
| +1,200% | +$42.1K | ﹤0.01% | 5909 |
|
|
2018
Q1 | $4K | Hold |
1
| – | – | ﹤0.01% | 6115 |
|
|
2017
Q4 | $4K | Hold |
1
| – | – | ﹤0.01% | 6103 |
|
|
2017
Q3 | $7K | Hold |
1
| – | – | ﹤0.01% | 5961 |
|
|
2017
Q2 | $6K | Sell |
1
-1
| -50% | -$6.92K | ﹤0.01% | 5892 |
|
|
2017
Q1 | $15K | Hold |
2
| – | – | ﹤0.01% | 5777 |
|
|
2016
Q4 | $26K | Hold |
2
| – | – | ﹤0.01% | 5565 |
|
|
2016
Q3 | $31K | Hold |
2
| – | – | ﹤0.01% | 5480 |
|
|
2016
Q2 | $34K | Sell |
2
-1
| -33% | -$13.7K | ﹤0.01% | 5335 |
|
|
2016
Q1 | $41K | Buy |
3
+1
| +50% | +$12.9K | ﹤0.01% | 5299 |
|
|
2015
Q4 | $45K | Buy |
2
+1
| +100% | +$15.8K | ﹤0.01% | 5325 |
|
|
2015
Q3 | $10K | Hold |
1
| – | – | ﹤0.01% | 5722 |
|
|
2015
Q2 | $17K | Hold |
1
| – | – | ﹤0.01% | 5666 |
|
|
2015
Q1 | $14K | Buy |
+1
| New | +$17.5K | ﹤0.01% | 5510 |
|
Other funds holding AGRX
Wells Fargo's AGRX Position: Q1 2024 in Review
Wells Fargo sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 19 shares — an estimated $37 sold.
Wells Fargo first reported a position in AGRX in Q1 2015 and held it in 33 quarters. The position peaked at $468K in Q4 2020. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.
- Wells Fargo reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
- Wells Fargo sold 19 Agile Therapeutics shares in Q1 2024, an estimated $37.
- Wells Fargo first reported a position in Agile Therapeutics in Q1 2015 and held it in 33 quarters.
- Wells Fargo's Agile Therapeutics position peaked at $468K in Q4 2020.
- 1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.
Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.